PDCD1 and non-small cell lung carcinoma: We evaluated the clinical relevance between the expression of PD-L2 in tumor tissues and anti-PD-1 immunotherapy (pembrolizumab) in 49 patients with NSCLC, as assessed by PD-L2 IHC score data from these patients.